PMID- 23056074
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121012
LR  - 20211021
IS  - 1896-9151 (Electronic)
IS  - 1734-1922 (Print)
IS  - 1734-1922 (Linking)
VI  - 8
IP  - 4
DP  - 2012 Sep 8
TI  - Simultaneous predictive value of NT-proBNP and CA-125 in patients newly diagnosed 
      with advanced heart failure: preliminary results.
PG  - 637-43
LID - 10.5114/aoms.2012.30287 [doi]
AB  - INTRODUCTION: New markers of cardiac events and new monitoring methods which can 
      improve care of patients with advanced heart failure (HF) are still being looked 
      for. MATERIAL AND METHODS: Sixty-five patients below 75 years old (mean age: 
      60.34 +/-9.54 years), hospitalized with the first manifestation of HF (left 
      ventricular ejection fraction </= 40%) and New York Heart Association (NYHA) class 
      II-IV symptoms, not optimally treated before the study, were included. Blood 
      samples for NT-proBNP and CA-125 were taken at baseline and during the 12-month 
      follow-up period. The doses of beta-adrenolytics and angiotensin-converting enzyme 
      (ACE) inhibitors were titrated to maximal tolerated ones according to the 
      guidelines in 1-year follow-up. The endpoint was established as overall death and 
      time to death. RESULTS: WORSE PROGNOSIS WAS OBSERVED IN GROUPS WITH: 1) NT-proBNP 
      and CA-125 above medians (OR = 492.9, p = 0.006), 2) baseline higher NT-proBNP 
      and CA-125 (HR = 0.016, p < 0.001), 3) increased or stable marker levels during 
      the first 3 months after treatment implementation. CONCLUSIONS: Elevated values 
      of NT-proBNP and CA-125 are found as the independent death risk factors. The 
      group with initial elevated NT-proBNP and CA-125 concentrations had a worse 
      prognosis. Changes in NT-proBNP and CA-125 levels after treatment implementation 
      predict unfavourable cardiovascular events with better CA-125 than NT-proBNP 
      performance.
FAU - Folga, Andrzej
AU  - Folga A
AD  - 3 Department of Internal Medicine and Cardiology, Medical University of Warsaw, 
      Poland.
FAU - Filipiak, Krzysztof J
AU  - Filipiak KJ
FAU - Mamcarz, Artur
AU  - Mamcarz A
FAU - Obrebska-Tabaczka, Elzbieta
AU  - Obrebska-Tabaczka E
FAU - Opolski, Grzegorz
AU  - Opolski G
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Arch Med Sci
JT  - Archives of medical science : AMS
JID - 101258257
PMC - PMC3460500
OTO - NOTNLM
OT  - CA-125
OT  - NT-proBNP
OT  - heart failure
OT  - mortality
OT  - prognosis
EDAT- 2012/10/12 06:00
MHDA- 2012/10/12 06:01
PMCR- 2012/09/08
CRDT- 2012/10/12 06:00
PHST- 2011/11/29 00:00 [received]
PHST- 2011/11/29 00:00 [revised]
PHST- 2011/11/30 00:00 [accepted]
PHST- 2012/10/12 06:00 [entrez]
PHST- 2012/10/12 06:00 [pubmed]
PHST- 2012/10/12 06:01 [medline]
PHST- 2012/09/08 00:00 [pmc-release]
AID - 19269 [pii]
AID - 10.5114/aoms.2012.30287 [doi]
PST - ppublish
SO  - Arch Med Sci. 2012 Sep 8;8(4):637-43. doi: 10.5114/aoms.2012.30287.